The global cancer biologics market size was valued at USD 130.7 billion in 2025 and is projected to grow from USD 139.46 billion in 2026 to USD 234.29 billion by 2034, registering a CAGR of 6.7% during the forecast period from 2026 to 2034. North America dominated the cancer biologics market with a market share of 41.6% in 2025.
Cancer biologics are medicines made from living organisms or biological materials and used to prevent, diagnose, or treat cancer. They include monoclonal antibodies, immunotherapies, cancer vaccines, and other targeted biological therapies. These treatments can help the immune system recognize cancer cells or target specific molecules involved in cancer growth.
Download a Free Sample To learn more about this report,
Targeted Therapies, Immunotherapy, and Cell-Based Treatments Are Advancing Cancer Biologics
The cancer biologics market is increasingly moving toward targeted therapies, immunotherapy, antibody-drug conjugates, and cell-based treatments. Manufacturers are developing therapies that selectively target cancer cells or activate the patient's immune system while improving treatment outcomes. Advances in precision medicine are also encouraging biomarker-driven therapies for specific cancer subtypes.
Antibody-Drug Conjugates and Combination Therapies Are Expanding Treatment Options
The cancer biologics market is also witnessing growing interest in antibody-drug conjugates and combination therapies. These approaches combine targeted biological mechanisms with established cancer treatments to improve therapeutic effectiveness. Increasing use of companion diagnostics is also supporting more selective treatment of patients based on tumor biomarkers.
Rising Cancer Treatment Burden Is Increasing Demand for Advanced Therapies
The growing number of patients requiring cancer treatment is supporting demand for effective therapeutic options across hematologic and solid tumors. Healthcare systems are seeking treatments that can improve response rates, extend survival, and address difficult-to-treat cancers. Continued development of therapies for previously underserved patient populations is therefore expanding the addressable market for cancer biologics.
High Treatment Costs and Complex Manufacturing Requirements
High treatment costs and complex manufacturing requirements remain major restraints for the cancer biologics market. Biologic medicines require specialized production facilities, advanced quality-control systems, and sophisticated distribution infrastructure. Their high prices can also create affordability and reimbursement challenges, while manufacturing requirements can increase development and commercialization costs.
Expansion of Biosimilars Can Improve Access to Established Cancer Biologics
The growing availability of biosimilars creates opportunities to expand access to established biologic cancer treatments while increasing competition in the biologics market. Biosimilar development can provide additional treatment options and potentially reduce costs for healthcare systems and patients. Continued regulatory efforts to streamline biosimilar development can further support market expansion.
Complex Manufacturing and Quality Control Can Hinder Advanced Biologic Development
Complex clinical development, manufacturing, quality control, and scalability remain important challenges for cancer biologics. These difficulties are particularly significant for cell-based therapies because production involves specialized processes, strict quality controls, and patient-specific manufacturing requirements. Maintaining consistent product quality while scaling production can increase development complexity and affect treatment availability.
Monoclonal Antibodies Segment Dominated the Market with a 58.7% Share in 2025
The monoclonal antibodies segment dominated the global cancer biologics market with a 58.7% share in 2025, accounting for USD 76.72 billion. Its leading position is supported by the widespread use of monoclonal antibodies in targeted cancer treatment, where they can recognize specific proteins or markers associated with cancer cells. Increasing adoption of precision medicine and continued development of antibody-based therapies are further supporting segment growth.
The growth factor segment is expanding due to its use in supporting patients undergoing cancer treatment, particularly by helping manage treatment-related complications. the blood and blood products segment continues to support oncology care through transfusion and supportive treatment applications. the vaccines and toxoids segment is also gaining attention as research and development activities continue to explore preventive and therapeutic approaches in cancer treatment.
Request Customizationto receive a tailored report.
Speak to an Analystto discuss market opportunities.
North America cancer biologics market accounted for 41.6% of the global market, reaching USD 54.37 billion in 2025, and is projected to grow at a CAGR of 7.42% during the forecast period. Growth is driven by the high prevalence of cancer, strong healthcare infrastructure, increasing adoption of targeted therapies, and substantial investments in oncology research and development. Growing use of monoclonal antibodies, immunotherapies, and precision medicine continues to strengthen regional market growth.
The US market was valued at approximately USD 47.85 billion in 2025, making it the largest contributor in North America. Increasing adoption of targeted biologics, advanced cancer treatments, immunotherapies, and precision medicine, along with strong pharmaceutical research and development activities, continues to support market growth.
Canada's market reached approximately USD 6.52 billion in 2025. Rising cancer treatment demand, expanding access to biologic therapies, increasing oncology research, and growing adoption of targeted and personalized treatments continue to support market expansion.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe cancer biologics market accounted for 27.3% of the global market, reaching USD 35.68 billion in 2025, and is projected to grow at a CAGR of 7.18% during the forecast period. Growth is supported by increasing cancer incidence, expanding access to advanced biologic therapies, and growing investments in oncology research and precision medicine. Increasing adoption of monoclonal antibodies and other targeted treatments continues to strengthen regional market demand.
The UK market was valued at approximately USD 8.92 billion in 2025. Increasing adoption of targeted cancer therapies, immunotherapies, advanced diagnostics, and personalized treatment approaches continues to support market growth.
Germany's market reached approximately USD 10.70 billion in 2025. Strong healthcare infrastructure, increasing cancer treatment demand, advanced pharmaceutical research, and growing adoption of biologic and targeted therapies continue to drive market expansion.
Asia Pacific cancer biologics market accounted for 22.4% of the global market, reaching USD 29.28 billion in 2025, and is projected to register the fastest CAGR of 9.36% during the forecast period. Growth is driven by increasing cancer prevalence, expanding healthcare infrastructure, rising healthcare expenditure, and improving access to advanced oncology treatments. Growing pharmaceutical investments and increasing adoption of targeted biologics and precision medicine are further supporting regional market growth.
Japan's market was valued at approximately USD 5.86 billion in 2025. Rising demand for advanced cancer treatments, an aging population, strong healthcare infrastructure, and increasing adoption of targeted biologics and immunotherapies continue to support market growth.
China's market reached approximately USD 17.57 billion in 2025, making it one of the largest contributors in Asia Pacific. Increasing cancer prevalence, expanding healthcare access, growing pharmaceutical investments, and rising adoption of biologics and advanced oncology therapies continue to accelerate market growth.
Middle East and Africa cancer biologics market accounted for 3.6% of the global market, totaling USD 4.71 billion in 2025, and is anticipated to grow at a CAGR of 6.94% during the forecast period. Growth is driven by increasing cancer burden, improving healthcare infrastructure, expanding access to advanced therapies, and rising investments in oncology care. Growing awareness and adoption of targeted cancer treatments are further supporting regional market expansion.
The UAE market was valued at approximately USD 0.47 billion in 2025. Increasing healthcare investments, development of advanced oncology facilities, growing adoption of targeted therapies, and rising demand for innovative cancer treatments continue to strengthen market growth.
Africa's market reached approximately USD 4.24 billion in 2025. Increasing cancer prevalence, improving healthcare infrastructure, expanding access to oncology treatments, and growing investments in cancer diagnosis and treatment continue to create growth opportunities across the region.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
CRISPR Gene Editing Market Size, Share, Growth, Analysis, 2034
Mass Spectrometry Market Size, Share, Growth, Analysis, 2034
Blood Testing Market Size, Share, Growth, Analysis, Report, 2034
3D Cell Culture Market Size, Share, Growth, Analysis, Report, 2034
3D Bioprinting Market Size, Share, Growth, Analysis, Report, 2034
United Kingdom Epigenetics Market Size, Trends, Top Share and Forecast to 2034
We are featured on:
sales@straitsresearch.com